Roelofzen JH, Aben KK, Oldenhof UT, Coenraads PJ, Alkemade HA, van de Kerkhof PC,
While they use the same active ingredient, equivalence to FDA-approved finished products should not be assumed
Second Natures published research shows strong 12-month outcomes, and their NHS partnerships since 2017 provide independent validation of their approach
During a period of high demand and limited supply, the FDA allowed pharmacies to compound GLP-1s to help patients maintain access while manufacturers scaled up production
(2023, July 18)
Su uso se estudia en personas con enfermedades cardacas o problemas de insuficiencia circulatoria, ya que puede mejorar la tolerancia al ejercicio y reducir los sntomas de claudicacin intermitente